Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Allergy Clin Immunol Pract ; 11(8): 2557-2567.e6, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37182569

RESUMEN

BACKGROUND: A guideline identifying when inpatients with penicillin or cephalosporin antibiotic allergy labels (PCAAL) can receive ß-lactam antibiotics increased ß-lactam receipt at a large northeastern US health care system. OBJECTIVE: To report outcomes of implementing a similar guideline and electronic order set (OS) at an independent academic health care system. METHODS: Penicillin/cephalosporin receipt (percentage of inpatients receiving full doses) and alternative antibiotic use (days of therapy per 1000 patient-days [DOT/1000PD]) were compared over 3 periods before (February 1, 2017, to January 31, 2018) and after guideline implementation (February 1, 2018, to January 31, 2019), and after OS implementation (February 1, 2019, to January 31, 2020) among inpatients with PCAAL admitted on medical services with access to guideline/OS and education (Medical-PCAAL, n = 8721), surgical services with access to guideline/OS without education (Surgical-PCAAL, n = 5069), and obstetrics/gynecology services without interventions (Ob/Gyn-PCAAL, n = 798) and inpatients without PCAAL admitted on the same services (Medical-No-PCAAL, n = 50,840; Surgical-No-PCAAL, n = 29,845; Ob/Gyn-No-PCAAL, n = 6109). χ2 tests were used to compare categorical variables, and analysis of variance was used to compare continuous and interrupted time series analyses (ITSA) to investigate the guideline/OS implementation effect on penicillin/cephalosporin receipt. RESULTS: In the Medical-PCAAL group, penicillin/cephalosporin receipt increased (58%-68%, P < .001), specifically for cefazolin (8%-11%, P = .02) and third- to fifth-generation cephalosporins (43%-48%, P = .04), and aztreonam use decreased (12 DOT/1000PD, P = .03). In the Medical-No-PCAAL group, penicillin/cephalosporin receipt increased (88%-90%, P = .004), specifically for penicillin (40%-44%, P < .001), without changes in aztreonam use. Significant changes were not observed in these outcomes on surgical or obstetrics/gynecology services. Per ITSA, guideline/OS implementation was associated with increased penicillin/cephalosporin receipt in the Medical-PCAAL group only. CONCLUSION: Guideline and OS implementation was associated with improved antibiotic stewardship on inpatient services that also received allergy education.


Asunto(s)
Hipersensibilidad a las Drogas , Hipersensibilidad , Humanos , Antibacterianos/efectos adversos , beta-Lactamas/efectos adversos , Pacientes Internos , Aztreonam , Penicilinas/efectos adversos , Cefalosporinas/uso terapéutico , Cefalosporinas/efectos adversos , Hipersensibilidad a las Drogas/tratamiento farmacológico , Hipersensibilidad/tratamiento farmacológico , Estudios Retrospectivos
2.
Lancet Planet Health ; 7(5): e381-e386, 2023 05.
Artículo en Inglés | MEDLINE | ID: mdl-37164514

RESUMEN

BACKGROUND: Large-scale wildfires in California, USA, are increasing in both size and frequency, with substantial health consequences. The capacity for wildfire smoke to displace microbes and cause clinically significant fungal infections is poorly understood. We aimed to determine whether exposure to wildfire smoke was associated with an increased risk of hospital admissions for systemic fungal infections. METHODS: In this population-based, retrospective study, we used hospital administrative data from 22 hospitals in California, USA, to analyse the association between wildfire smoke exposure and monthly hospital admissions for aspergillosis and coccidioidomycosis. We included hospitals that were members of the Vizient Clinical Data Base or Resource Manager during the study and excluded those that did not have complete reporting into Vizient during the study period. Smoke exposure was estimated using satellite-imaged smoke plumes in the hospital county. Incident rate ratios were calculated for all infection types 1 month and 3 months after smoke exposure. FINDINGS: Between Oct 1, 2014, and May 31, 2018, there were a median of 1638 annual admissions per hospital in the study sample. Individual patient demographics were not collected. We did not observe an association between smoke exposure and rate of hospital admission for aspergillosis. However, hospital admission for coccidioidomycosis increased by 20% (95% CI 5-38) in the month following any smoke exposure. Hospital admission increased by 2% (0-4) for every day that there had been smoke exposure in the previous month, after adjustment for temperature and temporal trend. Similar results were obtained with smoke exposure data from the 3 months before admission. INTERPRETATION: In the months following wildfire smoke exposure, California hospitals saw increased coccidioidomycosis infections. Given the projected increase in California wildfires and their expansion in endemic territories of soil-dwelling fungi, the ability for wildfire smoke to carry microbes and cause human disease warrants further research. FUNDING: None.


Asunto(s)
Aspergilosis , Coccidioidomicosis , Micosis , Incendios Forestales , Humanos , Material Particulado/efectos adversos , Estudios Retrospectivos , Coccidioidomicosis/inducido químicamente , Exposición a Riesgos Ambientales/efectos adversos , Humo/efectos adversos , California/epidemiología , Micosis/epidemiología , Micosis/inducido químicamente , Aspergilosis/inducido químicamente
3.
BMJ Case Rep ; 13(4)2020 Apr 29.
Artículo en Inglés | MEDLINE | ID: mdl-32354764

RESUMEN

We describe a case of opportunistic coinfections with Coccidioides immitis and Pneumocystis jirovecii following treatment with idelalisib, a phosphoinositide 3-kinase inhibitor, for chronic lymphocytic leukaemia. This is the first case of pulmonary coccidioidomycosis reported in association with idelalisib. We review challenges related to diagnosis of opportunistic infections in this context. This report illustrates (1) the uncommon occurrence of two opportunistic infections concurrently or in rapid succession, (2) the importance of maintaining a broad differential diagnosis in the setting of an atypical imaging finding, slow clinical response or when immunomodulatory drugs are used, and (3) the challenges associated with non-invasive serological testing in individuals with haematological malignancy on immunomodulatory therapy.


Asunto(s)
Antineoplásicos/efectos adversos , Coccidioidomicosis/diagnóstico , Huésped Inmunocomprometido , Pneumocystis carinii/aislamiento & purificación , Neumonía por Pneumocystis/diagnóstico , Purinas/efectos adversos , Quinazolinonas/efectos adversos , Anciano , Coccidioides/aislamiento & purificación , Coccidioidomicosis/complicaciones , Coccidioidomicosis/tratamiento farmacológico , Coinfección , Diagnóstico Diferencial , Humanos , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Masculino , Neumonía por Pneumocystis/complicaciones , Neumonía por Pneumocystis/tratamiento farmacológico , Tomografía Computarizada por Rayos X
5.
Open Forum Infect Dis ; 6(4): ofz134, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31024974

RESUMEN

Bergeyella cardium is a new species in the family Flavobacteriaceae that was recently described in 3 cases of native valve infective endocarditis. We report the first case of B. cardium prosthetic valve endocarditis, provide the first draft genome of this species, and review the microbiologic characteristics of this emerging pathogen.

6.
Dermatol Clin ; 30(3): 369-76, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22800545

RESUMEN

Total cumulative sun exposure is associated with the development of squamous cell and basal cell cancers, whereas intense intermittent sun exposure is associated with the development of melanoma. Exposure to UV radiation is the only known modifiable cause of melanoma, but the role of sunscreen in melanoma prevention remains somewhat controversial. This article discusses how UV radiation contributes to the pathogenesis of melanoma, how sunscreen modulates the action of UV radiation on the skin, and the effect of sunscreen on the risk of developing melanoma. A review of available sunscreen agents and their sun-protective properties is also included.


Asunto(s)
Melanoma/prevención & control , Neoplasias Cutáneas/prevención & control , Quemadura Solar/prevención & control , Luz Solar/efectos adversos , Protectores Solares , Rayos Ultravioleta/efectos adversos , Humanos , Melanoma/etiología , Riesgo , Conducta de Reducción del Riesgo , Neoplasias Cutáneas/etiología , Quemadura Solar/complicaciones , Protectores Solares/química , Protectores Solares/clasificación , Rayos Ultravioleta/clasificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA